Amgen, Sanofi, and Regeneron Pharmaceuticals Inc. have reported additional information about the cholesterol lowering drugs PCSK9 inhibitors. The studies were broadly consistent, showing the powerful cholesterol-lowering effects. However, both studies also reported a small but significant number of adverse neurocognitive effects in people taking the drugs. Via Forbes. Posted March 30, 2015.
–Alanna McCatty
